Tvardi Therapeutics (NASDAQ:TVRD) Stock Gets Downgrade from Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Sunday, Wall Street Zen reports.

TVRD has been the topic of a number of other reports. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, July 8th. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. Chardan Capital started coverage on shares of Tvardi Therapeutics in a research note on Tuesday, October 20th. They issued a “buy” rating for the company. BTIG Research dropped their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.40.

Tvardi Therapeutics Trading Up 1.6%

TVRD stock opened at $0.81 on Friday. Tvardi Therapeutics has a 12-month low of $0.77 and a 12-month high of $5.69. The business’s fifty day moving average price is $1.36 and its 200 day moving average price is $2.75.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, equities analysts anticipate that Tvardi Therapeutics will post -2.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $181,000. Susquehanna International Group LLP acquired a new position in shares of Tvardi Therapeutics during the second quarter worth about $63,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics during the second quarter worth about $34,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.